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INTRODUCTION
Histiocytic sarcoma (HS) is an extremely rare lymphohematopoietic malignant neoplasm. Mathe et al. in 1970 1 described a collection of malignant neoplastic cells with histologic features of large macrophages with abundant eosinophilic cytoplasm. He was the fi rst to introduce the term histiocytic sarcoma for tumors with histologic similarities to macrophages previously referred to as reticulosarcoma and later as histiocytic lymphoma. World Health Organization defi nes HS as a malignant proliferation of cells that shows the morphologic and immunophenotypic features of mature tissue histiocytes. 2 It accounts for less than 1% of hematologic malignancies 2 and a limited number of cases have been reported in medical literature. Most patients are adults and male predilection is found in some studies. HS may occur in lymph nodes, but the majority of cases present in a variety of extranodal sites, most commonly gastrointestinal tract, skin and soft tissues; involvement of multiple sites is also known. [2] [3] [4] [5] 
DISCUSSION
Histiocytic sarcoma of the stomach is extremely rare and only a small number of cases have been described. Much of what is known about it is from an analysis of a systematic review of reported fourteen cases in medical literature. 6 Gastric HS mostly occurred in middle age or elder with a mean of 57.9 years. 6 Patients usually presented with a long time abdominal pain before diagnosis; the other major symptoms were melena, dyspeptic and systemic symptoms. 6 HS showed no typical localization in the stomach. The tumor size in the cases described varied from 1.5 cm 6 to 20 cm. 7 Lesions could be ulcerative with erosive hemorrhage. 5, 8 Regional lymph nodes involvement was found in half of reviewed cases. 6 Gastric HS was described to involve multiple sites, including colon 3 , jejunum 5 , esophagus 9 , pancreas and liver. 6, 10 The imaging features of gastric HS are nonspecifi c and it is diffi cult to differentiate it from other gastric malignancies by radiological evaluation alone. 8 There is no accepted staging, but HS is typically an FDG-avid neoplasm 6, 11 and staging relies on bone marrow biopsy and CT or PET/CT scans to look for multifocal disease.
Histopathology diagnosis is based on the neoplastic cells which are usually highly atypical, and malignant nature of the lesions is suggested based on the morphology, although specifi c diagnosis using only biopsy specimen is diffi cult. Cases arising primarily at extranodal sites may cause a diagnostic pathological dilemma, especially in the absense of a high degree of atypia or pleomorphism of the tumor cells masquerading as an infl ammatory pseudotumor. 11 The diagnosis of HS relies predominantly on the confi rmation of its histiocytic lineage and the exclusion of other poorly differentiated tumors like lymphoma, carcinoma, sarcoma, and melanoma. 3 HS is defi ned immunophenotypically by expression of one or more histiocytic marker (CD68, CD163, lysozyme) and absence of Langerhans cell (CD1a, langerin), follicular dendritic cell (CD21, CD35) and myeloid cell (CD33, CD13, myeloperoxidase) markers. CD45 and HLA-DR are usually positive and there may be expression of S-100 protein, but usually weak or focal. They are typically negative for specifi c B-and T-cell markers, CD4 is often positive, the Ki-67 index is variable. [2] [3] [4] Total or subtotal gastrectomy was the main treatment in reviewed cases of patients with gastric HS, rarely combined with chemotherapy 6 ; half of them had regional lymph node metastases at the time of surgery. During follow up either local recurrence or distant metastasis were seen, and death due to the disease leaded to a survival time from 7 to 13 months, but the follow-up periods were relatively short, data was scarce and inconclusive. 6 Two of the reported cases of gastric HS patients survived for a relative long time -18 months 12 and 3 years 5 after surgery and chemotherapy, suggesting that postoperative chemotherapy might be favorable. 6 The patient we describe is a 69-year-old woman, presenting with epigastric pain, nausea and constitutional symptoms which suggested an illness that affected the whole body. Gastroscopic examination with biopsy was the initial diagnostic work-up, but due to limited tissue, no further immunohistochemical testing was performed and adenocarcinoma could not be ruled out. Excisional biopsy is the preferred diagnostic method for HS and in our patient distal subtotal gastrectomy was diagnostic and therapeutic approach. Lymph node metastases were found during the operation and body CT scans confi rmed enlarged abdominal lymph nodes during staging.
In our case the deeply infi ltrative growth of the tumor in the gastric wall and the presence of lymph node metastases indicated the malignant and aggressive nature of this tumor. The morphology was of a poorly differentiated malignant neoplasm. CD68 positivity confi rmed histiocytic derivation of the tumor cells and the absence of S-100 was consistent with mature histiocytes rather than Langerhans cells. Ki-67 positivity of 45% of the tumor cells indicated higher cell proliferation. Immunohistochemical staining excluded myeloid neoplasm, lymphoma, carcinoma, sarcoma, and melanoma.
Unfortunately, survival of our patient was less than 1 years -10 months after diagnosis due to the aggressive nature of the tumor and initially poor prognosis, because of the tumor size and the disseminated disease. Therapeutic options were limited by the patient's age and comorbidities.
Histiocytic sarcoma is usually an aggressive neoplasm with grim clinical course and poor response to therapy, although exceptions have been reported. Tumor size and stage are believed to be important prognostic factors. [2] [3] [4] 13 There are no accepted treatment guidelines for HS due to the rarity of the disease. The majority of the patients with HS present with systemic disease at diagnosis and outcomes for treating metastatic HS with surgery, chemotherapy, or radiotherapy are unsatisfactory. Treatments with monoclonal antibodies, immunomodulators and novel targeted agents are also reported in patients with HS. The prognosis, however, remains generally poor.
CONCLUSION
To the best of our knowledge, this is the fi rst case of histiocytic sarcoma of the stomach described in Bulgaria. It widens the differential diagnosis of gastric malignancies, and underlines the signifi cance of immunohistochemical examination for HS diagnosis. Since gastric HS is a rare disease the collection and evaluation of additional cases are important to obtain further progress in prognosis and guide treatment decisions.
